The company will produce its lutetium-177 (Lu-177) therapeutic isotope at the new facility, which will be capable of making more than 300,000 doses per year when it is operational in 2022. In the meantime, Shine is producing Lu-177 at its Building One site, already completed at Janesville.

The company will use 35,000 sq ft of the new complex for its headquarters, it said.